HELICOBACTER PYLORI INFECTIONS, Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)
Conditions
Keywords
intestinal microbioma, gastric microbioma, HELICOBACTER PYLORI INFECTIONS, Inflammatory Bowel Disease
Brief summary
Clinical and experimental data suggest that dysbiosis may play a pivotal role in the pathogenesis of intestinal bowel disease (IBD). However, to the best of our knowledge, the composition of gastric and of intestinal microbiome has never been investigated in a population with IBD according to the presence/absence of Helicobacter pylori (H. pylori) in the stomach.
Detailed description
H. pylori infection is one of the most widely spread infectious diseases in humans. Although the pathogenesis of IBD is unknown, this pathology could result from complex interactions between environmental factors and the intestinal microbiota, with dysbiosis likely being a key factor. In theory, H. pylori infection could be involved in the pathogenesis of IBD by inducing alterations in gastric and/or intestinal permeability or by causing immunological derangements. However, various studies indicate that the prevalence of H. pylori infection is low in patients with IBD, suggesting a protective role for this infection in the development of IBD. The objective of the study is to investigate the potential link between H. pylori infection and IBD. Another objective is to analyze the complex interactions between the gastric and intestinal microbiome in a population with IBD according to the presence or absence of H. pylori in the stomach. The study will be based on a prospective cohort of patients with IBD receiving medical care at the CHU of Guadeloupe.
Interventions
OTHERBiopsies
Gastric biopsies are taken during digestive endoscopy as part of routine clinical care. Two additional biopsies (one fundic and one antral) are planned for research purposes, specifically for metagenomic analysis of the gastric microbiome.
Sponsors
Centre Hospitalier Universitaire de la Guadeloupe
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients over 18 years old Patients with IBD from the CHU of Guadeloupe Patients benefiting from an investigation of H. pylori infection through gastric biopsies and/or serology at the time of diagnosis of IBD Patients affiliated to the French social security system Free informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research)
Exclusion criteria
Patients of less than18 years Patients having not given their writing informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of H. pylori infection in patients with Inflammatory Bowel Disease (IBD) | At the time of endoscopic evaluation (baseline only). | Presence of Helicobacter pylori infection determined using gastric biopsies collected during clinically indicated upper gastrointestinal endoscopy. Infection status will be confirmed by standard histological assessment performed as part of routine care. The prevalence will be expressed as the proportion of IBD patients with confirmed H. pylori infection among all included IBD patients in the cohort. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Demographic characteristics according to H. pylori infection status | Baseline. | Comparison of demographic characteristics (age, sex, ethnicity) between IBD patients with and without confirmed H. pylori infection. Data collected at baseline from medical records. |
| Biological inflammatory markers according to H. pylori infection status | Baseline. | Comparison of biological markers related to disease activity (e.g., C-reactive protein, fecal calprotectin) between IBD patients with and without confirmed H. pylori infection. |
| Clinical characteristics according to H. pylori infection status | Baseline. | Comparison of clinical characteristics (type of IBD, disease duration, clinical activity) between IBD patients with and without confirmed H. pylori infection. Data collected at baseline from medical records. |
| Prevalence of gastric intestinal metaplasia and dysplasia according to H. pylori infection status | Baseline. | Histological assessment of gastric biopsies to determine intestinal metaplasia or dysplasia, compared between groups with/without H. pylori. |
| Composition of the gastric microbiome according to H. pylori infection status | Baseline. | Metagenomic analysis of additional gastric biopsies (fundic + antral) to compare microbiome profiles between IBD patients with and without H. pylori. |
| IBD-related treatments according to H. pylori infection status | Baseline. | Comparison of ongoing therapeutic regimens (e.g., immunosuppressants, biologics, corticosteroids) between IBD patients with and without confirmed H. pylori infection. |
Countries
Guadeloupe
Contacts
Primary Contactgeorgette Saint-Georges, MD
Outcome results
None listed